Literature DB >> 8162478

Raynaud's phenomenon in rheumatoid arthritis.

W Grassi1, P Blasetti, P Core, C Cervini.   

Abstract

The prevalence of Raynaud's phenomenon in RA was retrospectively reviewed in 411 consecutive RA patients and in a control group of 919 consecutive outpatients with OA. Raynaud's phenomenon was found in 19 (4.6%) of 411 RA patients and in 52 (5.6%) of 919 patients with OA: its prevalence was 4.3% (13 cases) in RA inpatients and 5.4% (six cases) in RA outpatients. Among the RA patients, the prevalence of Raynaud's phenomenon was 7.5% in men (7% of inpatients, 8.8% of outpatients) and 3.2% in women (3% of inpatients, 3.9% of outpatients) (P = N.S.). Conversely, the prevalence of Raynaud's phenomenon in patients with OA was higher in women (6.5%) than in men (2.9%) (P = 0.045). Our study indicates that the reported association between Raynaud's phenomenon and RA cannot be confirmed on the basis of a retrospective assessment of its prevalence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162478     DOI: 10.1093/rheumatology/33.2.139

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  4 in total

1.  The association of Raynaud's syndrome with rheumatoid arthritis--a meta-analysis.

Authors:  Peter Hartmann; Melvin Mohokum; Peter Schlattmann
Journal:  Clin Rheumatol       Date:  2011-04-02       Impact factor: 2.980

Review 2.  The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

Review 3.  Raynaud's phenomenon in older adults: diagnostic considerations and management.

Authors:  S M Ling; F M Wigley
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 4.271

4.  Capillaroscopic pattern in inflammatory arthritis.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Microvasc Res       Date:  2012-03-09       Impact factor: 3.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.